W. Kimryn Rathmell

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• Mitochondrial potential reflects T cell fitness and function during cancer immunotherapy

  The Journal of Immunology · 2026-06-01

• Flipping the narrative on launching a rewarding career in academic medicine

  Nature Cancer · 2025-12-10

• Targeted Metabolomic Methods for ¹³ C Stable Isotope Labeling with Uniformly Labeled Glucose and Glutamine Using Liquid Chromatography–Tandem Mass Spectrometry (LC–MS/MS)

  Journal of Proteome Research · 2025-11-20 · 1 citations

• Assessing pathological response to neoadjuvant therapy in renal cell carcinoma: a systematic review and guidelines for sampling and reporting standards from the International Neoadjuvant Kidney Cancer Consortium

  The Lancet Oncology · 2025-10-01 · 8 citations

• A SETD2–CDK1–lamin axis maintains nuclear morphology and genome stability

  Nature Cell Biology · 2025-08-01 · 10 citations

• Correction: SETD2 loss sensitizes cells to PI3Kβ and AKT inhibition

  UNC Libraries · 2025-07-23

• SETD2 loss sensitizes cells to PI3Kβ and AKT inhibition

  UNC Libraries · 2025-07-23

• Vaccines in cancer treatment and prevention: the time is now

  Journal of Clinical Investigation · 2025-06-30 · 3 citations

• Potentiating cancer immunotherapies with modular albumin-hitchhiking nanobody–STING agonist conjugates

  Nature Biomedical Engineering · 2025-06-11 · 46 citations

• Abstract 5396: NDUFA4L2 inhibits oxidative phosphorylation to drive primary tumor escape

  Cancer Research · 2025-04-21

• Supplementary Figure S3 from A Phase II Trial of the WEE1 Inhibitor Adavosertib in <i>SETD2</i><i>-</i>Altered Advanced Solid Tumor Malignancies (NCI 10170)Preprint

  2025-03-28

• Supplementary Protocol S1 from A Phase II Trial of the WEE1 Inhibitor Adavosertib in <i>SETD2</i><i>-</i>Altered Advanced Solid Tumor Malignancies (NCI 10170)Preprint

  2025-03-28

• Supplementary Table S4 from A Phase II Trial of the WEE1 Inhibitor Adavosertib in <i>SETD2</i><i>-</i>Altered Advanced Solid Tumor Malignancies (NCI 10170)

  2025-03-28

• Supplementary Figure S2 from A Phase II Trial of the WEE1 Inhibitor Adavosertib in <i>SETD2</i><i>-</i>Altered Advanced Solid Tumor Malignancies (NCI 10170)Preprint

  2025-03-28

• Impaired oxidative phosphorylation drives primary tumor escape and metastasisPreprint

  bioRxiv (Cold Spring Harbor Laboratory) · 2025-01-09 · 3 citations

• Subset-specific mitochondrial stress and DNA damage shape T cell responses to fever and inflammation

  Science Immunology · 2024-09-20 · 31 citations

• Supplementary Table S4 from A Phase II Trial of the WEE1 Inhibitor Adavosertib in <i>SETD2</i><i>-</i>Altered Advanced Solid Tumor Malignancies (NCI 10170)

  2024-09-12

• Supplementary Protocol S1 from A Phase II Trial of the WEE1 Inhibitor Adavosertib in <i>SETD2</i><i>-</i>Altered Advanced Solid Tumor Malignancies (NCI 10170)Preprint

  2024-09-12

• Supplementary Figure S3 from A Phase II Trial of the WEE1 Inhibitor Adavosertib in <i>SETD2</i><i>-</i>Altered Advanced Solid Tumor Malignancies (NCI 10170)Preprint

  2024-09-12

• Supplementary Table S4 from A Phase II Trial of the WEE1 Inhibitor Adavosertib in <i>SETD2</i><i>-</i>Altered Advanced Solid Tumor Malignancies (NCI 10170)

  2024-09-12